Cancer Care Northwest

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer4 trials
• Multiple myeloma2 trials
• Ovarian cancer2 trials
• Childhood cancers1 trial
• Colorectal cancer1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Lung cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 23 trials
• Phase 33 trials
• Phase 1/22 trials
• Phase 11 trial

Status

• Completed3 trials
• Recruiting3 trials
• Terminated3 trials
• Active, not recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Veru Inc.3 trials
• Aadi Bioscience, Inc.1 trial
• Galera Therapeutics, Inc.1 trial
• Genmab1 trial
• Gradalis, Inc.1 trial
• and 4 more

Running trials

• Recruiting

  A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

  NCT07310420· Phase 1· TerSera Therapeutics LLC· Source

  Contact: Saritha Thumma, MD

• Recruiting

  CtDNA Based MRD Testing for NAC Monitoring in TNBC

  NCT06230185· Personalis Inc.· Source

  Contact: Ronaye Wagner

• Recruiting

  A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

  NCT03526835· Phase 1/2· Genmab· Source

• Active, not recruiting

  A Trial of Vigil for Participants With Ovarian Cancer

  NCT02346747· Phase 2· Gradalis, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Withdrawn

  Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

  NCT05079360· Phase 2· Veru Inc.· Source

• Terminated

  Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

  NCT05065411· Phase 3· Veru Inc.· Source

• Completed

  Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

  NCT05103358· Phase 2· Aadi Bioscience, Inc.· Source

• Terminated

  Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

  NCT04869943· Phase 3· Veru Inc.· Source

• Terminated

  Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

  NCT04476797· Phase 1/2· Galera Therapeutics, Inc.· Source

• Completed

  A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

  NCT03901963· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

  NCT01454297· Multiple Myeloma Research Foundation· Source